Other Information.
−Removed: None of our directors or officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (as defined in Item 408 (c) of Regulation S-K) during the first quarter of 2026 .
+Added: None of our directors or officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (as defined in Item 408 (c) of Regulation S-K) during the second quarter of 2026 .
See the Exhibit Index to this Quarterly Report immediately below and before the signature page hereto, which Exhibit Index is incorporated by reference as if fully set forth herein.
28 unchanged sentences
September 10, 2024
−Removed: Secured Promissory Note A-1, dated March 2, 2026.
+Added: Unsecured Promissory Note A-1, dated March 2, 2026.
March 6, 2026
20 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL (included in Exhibit 101)
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, formatted in Inline XBRL (included in Exhibit 101)
Furnished herewith.
1 unchanged sentence
ALLARITY THERAPEUTICS, INC.,
+Added: August 14, 2026
/s/ Thomas H.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 14, 2026
/s/ Jeffrey S.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.